News
LIMN
0.1130
-3.42%
-0.0040
Weekly Report: what happened at LIMN last week (0803-0807)?
Weekly Report · 1d ago
Liminatus Pharma Shareholders Approve Reverse Stock Split Plan
TipRanks · 6d ago
Weekly Report: what happened at LIMN last week (0727-0731)?
Weekly Report · 08/03 10:17
Liminatus Pharma Reports Improved Nasdaq Listing Compliance Status
TipRanks · 07/30 10:29
Weekly Report: what happened at LIMN last week (0720-0724)?
Weekly Report · 07/27 10:22
Liminatus Pharma Faces Nasdaq Delisting Risk, Plans Reverse Split
TipRanks · 07/24 21:18
Weekly Report: what happened at LIMN last week (0713-0717)?
Weekly Report · 07/20 10:18
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 07/17 17:05
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 07/17 12:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 07/16 17:05
Why is Cathie Wood’s ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD)
TipRanks · 07/16 13:00
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 07/16 12:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/14 21:05
Weekly Report: what happened at LIMN last week (0706-0710)?
Weekly Report · 07/13 10:20
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 07/10 12:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 07/08 12:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/07 21:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 07/07 12:05
Liminatus Pharma Closes InnocsAI Merger and Share Issuance
TipRanks · 07/06 13:27
Weekly Report: what happened at LIMN last week (0629-0703)?
Weekly Report · 07/06 10:24
More
Webull provides a variety of real-time LIMN stock news. You can receive the latest news about Liminatus Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LIMN
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.